Masonic Cancer Center welcomes Dr. Carla Rothlin as new co-leader of Immunology Program
The Masonic Cancer Center, University of Minnesota (MCC), is excited to announce that internationally recognized immunologist Carla Rothlin, PhD, will join MCC as co-leader of the Immunology Program in August 2025.
Dr. Rothlin, who comes to Minnesota from Yale University, will fill the leadership role currently held by MCC Interim Director Jeffrey Miller, MD, and will partner with Yoji Shimizu, PhD, who has served as Immunology Program co-leader since MCC’s inception in 1998! Dr. Shimizu’s decades-long leadership has been pivotal in shaping MCC’s immunology research, making this collaboration an especially significant milestone for the center.
In addition to her new role at MCC, Dr. Rothlin will serve as director of the University of Minnesota’s Center for Immunology (CFI), hold the Andersen Chair in Immunology, and be appointed as a professor in the Department of Laboratory Medicine and Pathology. Her research explores immunobiology, immune homeostasis, and receptor tyrosine kinases, critical areas for advancing cancer immunotherapy and understanding tumor-immune interactions.
MCC extends deep gratitude to Dr. Miller for his dedicated leadership of the Immunology Program and congratulates Dr. Rothlin on this new chapter. Her partnership with Dr. Shimizu represents a powerful combination of long-standing expertise and fresh vision, positioning MCC’s Immunology Program for continued excellence and innovation in cancer research.
We look forward to welcoming Dr. Rothlin to Minnesota and to the Masonic Cancer Center community.